Germany's G-BA Sets Out Financial-Based Criteria For Assessing Drugs Already On The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany's senior reimbursement body, the G-BA, has set out criteria – based on the financial success of products – to evaluate drugs already on the market.
You may also be interested in...
Januvia And Onglyza In, Galvus Out, As Germany Evaluates Older Drugs
Germany’s G-BA has panned Novartis’ Galvus, but retained Merck’s Januvia and Bristol/AstraZeneca’s Onglyza as it starts culling older drugs.
German State Court Ruling Against Novartis Confirms Legality of HTA For Older Products
A State Social Court of Berlin-Brandenburg ruling against Novartis means that Germany's reimbursement bodies can move forward with the benefit assessment of older pharmaceutical products.
Xolair’s Price Discount For NICE Is Ominous Sign For Older Products
Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.